Graft Polymer (UK) Plc announced that it has filed a utility patent application (provisional) with the United States Patent and Trademark Office (USPTO) for the use of its proprietary and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for the delivery of drugs for the treatment of substance use disorders. The provisional patent application, titled 'Composition and methods for substance use disorders (SUDS) using a self-nanoemulsifying drug delivery systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS platform to enhance the bioavailability, pharmacokinetics, and stability of therapeutics used in the treatment of substance use disorders many of which have poor solubility, leading to suboptimal drug delivery and posing an obstacle to successful formulation. This approach aims to leverage the Company's existing advanced biopolymer expertise to address significant unmet medical needs in addiction therapy.

The filing of this patent marks further progress in the Company's strategic focus on the healthcare industry, following the disposal of its industrial plastic manufacturing unit, Graft Polymer D.O.O, as announced on 3 May 2024. This disposal has enabled the Company to focus its attention and resources on its Graft Bio division, which represents, in the Directors' opinion, strong prospectivity through its intellectual property (IP), licensing agreements, and sales contracts.